title: Budget impact analysis of switching to darunavir/ritonavir monotherapy for HIV-infected people in Spain.
authors.forename: Juan
authors.initials: J
authors.lastname: Pasquau
authors.forename: Joana
authors.initials: J
authors.lastname: Gostkorzewicz
authors.forename: Francisco
authors.initials: F
authors.lastname: Ledesma
authors.forename: Anne
authors.initials: A
authors.lastname: Anceau
authors.forename: Andrew
authors.initials: A
authors.lastname: Hill
authors.forename: Christiane
authors.initials: C
authors.lastname: Moecklinghoff
mesh_terms: D023241:Antiretroviral Therapy, Highly Active; D002017:Budgets; D000069454:Darunavir; D015658:HIV Infections / Q000188:drug therapy*; D017320:HIV Protease Inhibitors / Q000008:administration & dosage / Q000191:economics* / Q000627:therapeutic use; D006801:Humans; D019438:Ritonavir / Q000008:administration & dosage / Q000191:economics* / Q000627:therapeutic use; D013030:Spain; D013449:Sulfonamides / Q000008:administration & dosage / Q000191:economics* / Q000627:therapeutic use
chemical_list: D017320:HIV Protease Inhibitors; D013449:Sulfonamides; D019438:Ritonavir; D000069454:Darunavir